What is the long-term trend for BioCryst Pharmaceuticals's change in deferred revenue?

Over 3 years (2021 to 2024), BioCryst Pharmaceuticals's change in deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $1.28M to $0.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

BioCryst Pharmaceuticals BCRX Change in Deferred Revenue

Change in Deferred Revenue at other companies

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

Ultragenyx PharmaceuticalRARE

$0+100%

BridgeBio PharmaBBIO

-$2.38M+7.5%

Arrowhead ResearchARWR

$163.36M—

ALN

Alnylam PharmaceuticalsALNY

-$1.63M+94.0%

CRISPR TherapeuticsCRSP

-$427K+48.2%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's change in deferred revenue?: BioCryst Pharmaceuticals (BCRX) reported change in deferred revenue of -$749K in Q1 2026.
What is the long-term trend for BioCryst Pharmaceuticals's change in deferred revenue?: Over 3 years (2021 to 2024), BioCryst Pharmaceuticals's change in deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $1.28M to $0.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.